research Treatment of Alopecia Areata with Oral JAK Inhibitor : Focusing on Clinical Outcomes with Baricitinib
Baricitinib is an effective treatment for severe alopecia areata.
Search
for
Sort by
Research
120-150 / 526 results 
research The Role of Janus Kinase Inhibitors in Dermatology
Janus Kinase Inhibitors are promising new treatments for various skin conditions due to their effectiveness and safety.
research Comparative efficacy and safety of JAK inhibitors in the treatment of moderate-to-severe alopecia areata: a systematic review and network meta-analysis
Brepocitinib 30mg is most effective for moderate-to-severe alopecia areata, but ritlecitinib 50mg may offer a better balance of safety and effectiveness.
research Tumor necrosis factor inhibitors and janus kinase inhibitors in the treatment of cicatricial alopecia: A systematic review
Tofacitinib and adalimumab are promising treatments for cicatricial alopecia with few side effects.
research Alopecia Areata, triggered by psychological stress and successfully treated with a Janus kinase inhibitor. Case report
Stress-related hair loss was reversed with a special medication.
research Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study
Baricitinib is effective and safe for treating severe alopecia areata.
research Sterol Intermediates of Cholesterol Biosynthesis Inhibit Hair Growth and Trigger an Innate Immune Response in Cicatricial Alopecia
Cholesterol-related compounds can stop hair growth and cause inflammation in a type of scarring hair loss.
research Tofacitinib (Selective Janus Kinase Inhibitor 1 and 3): A promising therapy for the treatment of alopecia areata: A case report of six patients
Tofacitinib helped regrow hair in patients with alopecia, with few side effects.
research LB1034 Meta-analysis of scalp transcriptome defines alopecia areata subtypes and molecular response to four (4) treatments with jak inhibiting properties
JAK inhibitors improve hair growth in alopecia areata, especially in patchy types.
research Pharmacologic inhibition of JAK-STAT signaling promotes hair growth
Blocking JAK-STAT signaling can lead to hair growth.
research Janus kinase inhibitors for alopecia areata: A narrative review
Janus kinase inhibitors can regrow hair in alopecia areata but may cause side effects and hair loss may return if treatment stops.
research JAK-Inhibitors Beyond the Label: Emerging Applications in Dermatology
JAK inhibitors show promise for treating various skin disorders effectively and safely.
research Efficacy and Tolerability of Brevilin-A, a Natural JAK Inhibitor, in Pediatric Alopecia Areata: A Case Series
Brevilin-A is a safe and effective treatment for mild to moderate alopecia areata in children.
research Are Janus kinase (JAK) inhibitors beneficial in the treatment of androgenic alopecia?
JAK inhibitors do not improve hair regrowth in androgenic alopecia but may prevent further hair loss.
research Treatment of an alopecia areata patient with tofacitinib results in regrowth of hair and changes in serum and skin biomarkers
A patient with alopecia areata regrew hair after taking tofacitinib and showed changes in certain blood and skin markers.
research Clinical evidence for JAK inhibition in alopecia areata: A comprehensive review
JAK inhibitors effectively regrow hair in alopecia areata but hair loss often returns after stopping treatment.
research Alopecia areata: Animal models illuminate autoimmune pathogenesis and novel immunotherapeutic strategies
Animal models have helped understand hair loss from alopecia areata and find new treatments.
research JAK 1-3 inhibitors and TYK-2 inhibitors in dermatology: Practical pearls for the primary care physician
Primary care doctors need to monitor JAK and TYK-2 inhibitors carefully for skin conditions.
research Alopecia Areata: Case report and review of pathophysiology and treatment with Jak inhibitors
JAK inhibitors like tofacitinib may effectively treat Alopecia Areata.
research Improvement of Psoriasis, Psoriatic Arthritis, and Alopecia Universalis during Treatment with Tofacitinib: A Case Report
Tofacitinib treatment significantly improved a patient's psoriasis, psoriatic arthritis, and alopecia universalis.
research 1322 Molecular profiling of frontal fibrosing alopecia (FFA) reveals TH1 and JAK-STAT up-regulation with no suppression of hair keratins
Frontal fibrosing alopecia shows increased inflammation and JAK-STAT pathway activity without reduced hair proteins.
research Role of topical tofacitinib in autoimmune skin disorders: An expert opinion
Topical tofacitinib is a safe and effective treatment for autoimmune skin disorders.
research Novel Janus Kinase Inhibitors in the Treatment of Dermatologic Conditions
JAK inhibitors show promise for treating various skin diseases.
research Upadacitinib in dermatologic therapy: Emerging evidence and expanding indications
Upadacitinib effectively treats skin conditions like eczema and psoriasis and is becoming more widely used and affordable.
research Use of oral Janus kinase inhibitors for the treatment of severe alopecia areata: narrative review and real-world experience
Janus kinase inhibitors help some people with severe alopecia areata regrow hair, but not everyone responds, and relapses can happen.
research 1325 Age-dependent loss of the stemness and antimicrobial defense function of dermal fibroblasts is mediated by TGFbeta
Aging reduces skin cell renewal and defense against germs due to TGFbeta, but blocking TGFbeta could help restore these functions.
research P88 Real-world evidence on efficacy and safety of Janus Kinase inhibitors in the treatment of moderate to severe active Ulcerative Colitis
Janus Kinase inhibitors effectively induce remission in Ulcerative Colitis with an acceptable safety profile.
research An overview of JAK/STAT pathways and JAK inhibition in alopecia areata
Blocking JAK/STAT pathways can help treat hair loss from alopecia areata.
research The relative efficacy of monotherapy with Janus kinase inhibitors, dupilumab and apremilast in adults with alopecia areata: Network meta‐analyses of clinical trials
JAK inhibitors are more effective and safer for treating alopecia areata than dupilumab and apremilast.
research 1313 Fzd2 controls multiple aspects of epidermal development through distinct signaling mechanisms
Fzd2 is important for skin and hair development through various signaling ways.